SAN FRANCISCO — Boston Scientific Corp.'s (Marlborough, Mass.) Synergy bioabsorbable polymer drug-eluting stent (DES) system and the Watchman left atrial appendage (LAA) closure device continue to be two pivotal products for the company going into 2016. The firm discussed the impact the technologies would have on it and discussed how transformational each product was going to be during the during a breakout session at the 34th annual J.P. Morgan Healthcare conference. Read More
